花旗发表研究报告指，荣昌生物(09995.HK) 上半年收入按年增长433%，亏转盈赚46.6亿元人民币。管理层表示，剔除BD收入后上半年净亏损约2,600万元人民币，预期剔除BD收入后，2026财年可实现收支平衡。该行表示，泰它西普及维迪西妥单抗展现强劲的按季销售增长，又相信RC148交易可重塑公司的增长轨道。该行上调公司2026至28年的收入预测3%、22%及18%，并将每股盈测调升至8.5元...
Source Link花旗发表研究报告指，荣昌生物(09995.HK) 上半年收入按年增长433%，亏转盈赚46.6亿元人民币。管理层表示，剔除BD收入后上半年净亏损约2,600万元人民币，预期剔除BD收入后，2026财年可实现收支平衡。该行表示，泰它西普及维迪西妥单抗展现强劲的按季销售增长，又相信RC148交易可重塑公司的增长轨道。该行上调公司2026至28年的收入预测3%、22%及18%，并将每股盈测调升至8.5元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.